z-logo
Premium
Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies
Author(s) -
Statland Jeffrey M.,
Shah Bharati,
Henderson Don,
Van Der Maarel Silvere,
Tapscott Stephen J.,
Tawil Rabi
Publication year - 2015
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.24621
Subject(s) - facioscapulohumeral muscular dystrophy , medicine , muscular dystrophy , pathology , clinical trial , disease , neuromuscular disease
As we move toward planning for clinical trials in facioscapulohumeral muscular dystrophy (FSHD), a better understanding of the clinical relationship with morphological changes in FSHD muscle biopsies will be important for stratifying patients and understanding post‐therapeutic changes in muscle. Methods: We performed a prospective cross‐sectional study of quadriceps muscle biopsies in 74 genetically confirmed FSHD participants (64 with FSHD type 1 and 10 with FSHD type 2). We compared a 12‐point muscle pathology grade to genetic mutation, disease severity score, and quantitative myometry. Results: Pathology grade had moderate correlations with genetic mutation (rho = –0.45, P  < 0.001), clinical severity score (rho = 0.53, P  < 0.001), disease duration (rho = 0.31, P  = 0.03), and quantitative myometry (rho = –0.47, P  < 0.001). We found no difference in the frequency of inflammation between FSHD types 1 and 2. Conclusions: The pathology grade of quadriceps muscle may be a useful marker of disease activity in FSHD, and it may have a role in stratification for future clinical trials. Muscle Nerve 52: 521–526, 2015

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom